Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration

Radioiodine ((131)I) therapy (RAI) has been utilized for treating differentiated thyroid cancer (DTC) for decades, and its uses can be characterized as remnant ablation, adjuvant therapy (RAT) or treatment for known diseases. Compared with the definite (131)I treatment targets for remnant ablation a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yu-qing, Sun, Di, Zhang, Xin, Zhang, Ying-qiang, Lin, Yan-song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747769/
https://www.ncbi.nlm.nih.gov/pubmed/36531486
http://dx.doi.org/10.3389/fendo.2022.994288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747769/
https://www.ncbi.nlm.nih.gov/pubmed/36531486
http://dx.doi.org/10.3389/fendo.2022.994288

Ejemplares similares